Oncogenic kinase signalling

Nature

Volumn 411, Issue 6835, 2001, Pages 355-365

  Blume Jensen, Peter ^a,b   Hunter, Tony ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITION; ENZYME KINETICS; ENZYMES; LIPIDS;

MULTICELLULAR COMMUNICATION;

ONCOLOGY;

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAPAMYCIN; S6 KINASE;

CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; METAZOON; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; HUMANS; MUTATION; NEOPLASMS; ONCOGENE PROTEIN V-AKT; ONCOGENE PROTEINS; ONCOGENES; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RETROVIRIDAE PROTEINS, ONCOGENIC; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION;

MAMMALIA; METAZOA;

EID: 0035902180     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35077225     Document Type: Review

References (93)

1. Hunter, T. Signaling - 2000 and beyond. Cell 100, 113-127 (2000).
2. Pawson, T. & Nash, P. Protein-protein interactions define specificity in signal transduction. Genes Dev. 14, 1027-1047 (2000).
3. Reed, J. C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17, 2941-2953 (1999).
4. Hunter, T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Phil. Trans. R. Soc. Lond. B 353, 583-605 (1998).
5. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
6. Plowman, G. D., Sudarsanam, S., Bingham, J., Whyte, D. & Hunter, T. The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms. Proc. Natl Acad. Sci. USA 96, 13603-13610 (1999)
7. Robinson, D. R., Wu, Y. M. & Lin, S. E. The protein tyrosine kinase family of the human genome Oncogene 19, 5548-5557 (2000).
8. Futreal, P. A. et al. Cancer and genomics. Nature 409, 850-852 (2001).
9. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
10. Blume-Jensen, P. & Hunter, T. in Encyclopedia of Cancer (ed. Bertino, J. R.) (Academic, San Diego, in the press).
11. Heldin, C. H. Dimerization of cell surface receptors in signal transduction. Cell 80, 213-223 (1995).
12. Hubbard, S. R. & Till, J. H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373-398 (2000).
13. Hubbard, S. R., Mohammadi, M. & Schlessinger, J. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 273, 11987-11990 (1998).
14. Jiang, G. & Hunter, T. Receptor signaling: when dimerization is not enough. Curr. Biol. 9, R568-R571 (1999).
15. Shewchuk, L. M. et al. Structure of the Tic2 RTK domain. Self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure Fold. Des. 8, 1105-1113 (2000).
16. Binns, K. L., Taylor, P. P., Sicheri, F., Pawson, T. & Holland, S. J. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol. Cell. Biol. 20, 4791-4805 (2000).
17. Irusta, P. M. & DiMaio, D. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation. EMBO J. 17, 6912-6923 (1998).
18. Hirota, S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580 (1998).
19. Meshinchi, S. et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97, 89-94 (2001).
20. Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HFR2 action in breast cancer. Oncogene 19, 6102-6114 (2000).
21. Jhiang, S. M. The RET proto-oncogene in human cancers. Oncogene 19, 5590-5597 (2000).
22. Santoro, M. et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267, 381-383 (1995).
23. Zhou, S. et al. Catalytics specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373, 536-539 (1995).
24. Bocciardi, R. et al. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15, 2257-2265 (1997).
25. Murakami, H. et al. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem. Biophys. Res. Commun. 262, 68-75 (1999).
26. Smith-Hicks, C. L., Sizer, K. C., Powers, J. F., Tischler, A. S. & Costantini, F. C -cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO J. 19, 612-622 (2000).
27. van Weering, D. H. & Bos, J. L. Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res. 154, 271-281 (1998).
28. Ashman, L. K. The biology of stem cell factor and its receptor C-kit. Int. J. Biochem. Cell Biol. 31, 1037-1051 (1999).
29. Besmer, P. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. Curr. Opin. Cell Biol. 3, 939-946 (1991).
30. Blume-Jensen, P. & Hunter, T. in Cancer Research - An Encyclopedic Reference (ed. Schwab, M.) (Springer, in the press).
31. Kozlowski, M. et al. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol. Cell. Biol. 18, 2089-2099 (1998).
32. Lennartsson, J. et al. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18, 5546-5553 (1999).
33. Taniguchi, M. et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 59, 4297-4300 (1999).
34. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogenic in papillary renal carcinomas. Nature Genet. 16, 68-73 (1997).
35. Chian, R. et al. P13 kinase mediates transformation of hematopoietic cells by the V816 c-kit mutant. Exp. Hematol. 28, 1491 (2000).
36. Blume-Jensen, P., Janknecht, R. & Hunter T. The kit receptor promotes cell survival via activation of P1 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8, 779-782 (1996).
37. Chen, H. E., Chang, S., Trub, T. & Neel, B. G. Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase. SHPTP1. Mol. Cell. Biol. 16, 3685-3697 (1996).
38. Paulson, R. E., Vesely, S., Siminovitch, K. A. & Bernstein, A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nature Genet. 13, 309-315 (1996)
39. Piao, X., Paulson, R., van der Geer, P., Pawson, T. & Bernstein, A. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl Acad. Sci. USA 93, 14665-14669 (1996).
40. Beghini, A. et al. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. Hum. Mol Genet. 9, 2297-2304 (2000).
41. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561-566 (1996).
42. Heinrich, M. C., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925-932 (2000).
43. Stehelin, D., Varmus, H. E., Bishop, J. M. & Vogt, P. K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260, 170-173 (1976).
44. Bjorge, J. D., Jakymiw, A & Fujita, D. J. Selected glimpses into the activation and function of src kinase. Oncogene 19, 5620-5635 (2000).
45. Sicheri, F. & Kuriyan, J. Structures of Src-family tyrosine kinases. Curr. Opin. Struct. Biol. 7, 777-785 (1997).
46. Irby, R. B. et al. Activating SRC mutation in a subset of advanced human colon cancers Nature Genet. 21, 187-190 (1999).
47. Nowell, P. & Hungerford, D. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497 (1960).
48. Vigneri, P. & Wang, J. Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nature Med. 7, 228-234 (2001).
49. Wang, J. Y. Regulation of cell death by the abl tyrosine kinase. Oncogene 19, 5643-5650 (2000).
50. Stiewe, T. & Putzer, B. M. Role of the p53-homologue p73 in F2F1-induced apoptosis. Nature Genet. 26, 464-469 (2000).
51. Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A. & Pendergast, A. M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13, 2400-2411 (1999).
52. McWhirter, J. R., Galasso, D. L. & Wang, J. Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13, 7587-7595 (1993).
53. Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356 (2000).
54. Hallek, M. et al. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br. J. Haematol. 94, 5-16 (1996).
55. Gesbert, F., Sellers, W. R., Signoretti, S., Loda, M. & Griffin, J. D. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J. Biol. Chem. 275, 39223-39230 (2000).
56. Skorski, T. et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16, 6151-6161 (1997).
57. Horita, M. et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med. 191, 977-984 (2000).
58. Ihle, J. N., Nosaka, T., Thierfelder, W., Quelle, F. W. & Shimoda, K. Jaks and Stats in cytokine signaling. Stem Cells 15(Suppl. 1), 105-111; discussion, 112 (1997).
59. Darnell, J. E. STATs and gene regulation. Science 277, 1630-1635 (1997).
60. Bromberg, J. F. Activation of STAT proteins and growth control. BioEssays 23, 161-169 (2001).
61. Bowman, T., Garcia, R., Turkson, J. & Jove, R. STATs in oncogenesis. Oncogene 19, 2474-2488 (2000).
62. Haspel, R. L. & Darnell, J. E. A nuclear protein tyrosine phosphatase is required for the inactivation of Stat. Proc. Natl Acad Sci. USA 96, 10188-10193 (1999).
63. Yasukawa, H., Sasaki, A. & Yoshimura, A. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18, 143-164 (2000).
64. Peeters, P. et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535-2540 (1997).
65. Lacronique, V. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997).
66. Schwaller, J. et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell 6, 693-704 (2000).
67. Rosa Santos, S. C., Dumon, S., Mayeux, P., Gisselbrecht, S. & Gouilleux, F. Cooperation between STATS and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene 19, 1164-1172 (2000).
68. Migone, T. S. et al. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. Mol. Cell. Biol. 18, 6416-6422 (1998).
69. Pfeffer, L. M. et al. STAT3 as an adapter to couple phosphatidylinositol 3-kindse to the IFNAR1 chain of the type 1 interferon receptor. Science 276, 1418-1420 (1997).
70. Vanhaesebroeck, B. & Alessi, D. R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346(3), 561-576 (2000).
71. Schmelzle, T. & Hall, M. N. TOR, a central controller of cell growth. Cell 103, 253-262 (2000).
72. Pyronnet, S. & Sonenberg, N. Cell-cycle-dependent translational control. Curr. Opin. Gen. Dev. 11, 13-18 (2001).
73. Dafner, A. & Thomas, G. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res. 253, 100-109 (1999).
74. Blume-Jensen, P. & Hunter, T. in Encyclopedia of Cancer (ed. Bertino, J. R.) (Academic, San Diego, in the press).
75. Bellacosa, A. et al. Structure, expression and chromosomal mapping of c-akt: relationship tov-akt and its implications. Oncogene 8, 745-754 (1993).
76. Toker, A. & Newton, A. C. Cellular signaling: pivoting around PDK-1. Cell 103, 185-188 (2000).
77. Meier, R. & Hemmings, B. A. Regulation of protein kinase B. J. Recept. Signal. Transduct. Res. 19, 121-128 (1999).
78. Williams, M. R. et al. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr. Biol. 10, 439-448 (2000).
79. Datta, S. R., Brunet, A. & Greenburg, M. E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927 (1999).
80. Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511 (1998).
81. Zhuo, B. P. et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biol. 3, 245-252 (2001).
82. Chang, H. W. et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276, 1848-1850 (1997).
83. Shayesteh, I. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21, 99-102 (1999).
84. Jimenez, C. et al. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. 17, 743-753 (1998).
85. KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nature Genet. 27, 222-224 (2001).
86. Sasaki, T. et al. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ. Nature 406, 897-902 (2000).
87. Brennan, P., Babbage, J. W., Thomas, G. & Cantrell, D. p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol. Cell. Biol. 19, 4729-4738 (1999).
88. Feng, L. X., Ravindranath, N. & Dym, M. Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J. Biol. Chem. 275, 25572-25576 (2000)
89. Masahiro, A., Blazek, E. & Vogt, P. K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl Acad. Sci. USA 98, 136-141 (2001).
90. Cichowski, K. & Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593-604 (2001).
91. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-Abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
92. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
93. Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N. Engl. J. Med. 344, 1052-1056 (2001).